Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease?

TitleIs ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease?
Publication TypeJournal Article
Year of Publication2016
AuthorsBa M, Kong M, Li X, Ng KPin, Rosa-Neto P, Gauthier S
JournalTransl Neurodegener
Volume5
Pagination20
Date Published2016
ISSN2047-9158
Abstract

Amyloid plaques are pathological hallmarks of Alzheimer's Disease (AD) and biomarkers such as cerebrospinal fluid (CSF) β-amyloid 1-42 (Aβ1-42) and amyloid positron emission tomographic (PET) imaging are important in diagnosing amyloid pathology in vivo. ɛ4 allele of the Apolipoprotein E gene (ApoE ɛ 4), which is a major genetic risk factor for late onset AD, is an important genetic biomarker for AD pathophysiology. It has been shown that ApoE ɛ 4 is involved in Aβ deposition and formation of amyloid plaques. Studies have suggested the utility of peripheral blood ApoE ɛ 4 in AD diagnosis and risk assessment. However it is still a matter of debate whether ApoE ɛ 4 status would improve prediction of amyloid pathology and represent a cost-effective alternative to amyloid PET or CSF Aβ in resource-limited settings in late onset AD. Recent research suggest that the mean prevalence of PET amyloid-positivity is 95% in ApoE ɛ 4-positive AD patients. This short review aims to provide an updated information on the relationship between ApoE ɛ 4 and amyloid biomarkers.

DOI10.1186/s40035-016-0067-z
Alternate JournalTransl Neurodegener
PubMed ID27891223
PubMed Central IDPMC5112745

  • Douglas Hospital
  • Dobell Pavillion
  • Brain imaging centre